Importantly, this improvement did not come with a higher risk of major bleeding, a common concern with blood-thinning drugs. The findings were presented at the European Society of Cardiology Congress in Madrid and published simultaneously in The Lancet.

Why Aspirin Was the Default Choice

For many years, doctors have routinely prescribed low-dose aspirin to patients with coronary artery disease—the most common type of heart disease—to help lower the risk of blood clots. Aspirin makes blood less likely to clot, lowering the chances of blockages in narrowed arteries. This approach has been central to preventing repeat heart attacks and strokes.

Despite its popularity, aspirin has always carried a risk of gastrointestinal bleeding and, in some cases, has not been as effective as hoped over the long term.

Clopidogrel, which has been in use since the late 1990s, works differently by blocking a platelet receptor called P2Y₁₂. It has usually been given alongside aspirin as part of dual antiplatelet therapy or prescribed to patients who cannot tolerate aspirin. Until now, it was not considered a superior option for long-term use on its own.

What the Study Found

The new analysis combined data from seven clinical trials that followed nearly 29,000 patients with coronary artery disease. These patients came from different backgrounds and included those who had undergone stent placement or had experienced acute coronary syndromes.

Across this broad group, clopidogrel consistently performed better than aspirin. Patients taking clopidogrel experienced fewer major cardiovascular and cerebrovascular events, while rates of bleeding were essentially the same as those in the aspirin group.

Patients predicted to have a weaker response to clopidogrel because of genetic or clinical factors still showed better outcomes than those taking aspirin.

Evidence from Other Clinical Trials

The results align with findings from earlier studies. The HOST-EXAM trial, which followed more than 5,000 patients in South Korea after stent placement, reported fewer heart attacks, strokes, and bleeding complications in patients treated with clopidogrel instead of aspirin over almost six years.

Another trial, SMART-CHOICE 3, found that clopidogrel reduced the combined risk of death, heart attack, and stroke in high-risk patients compared to aspirin, again without raising bleeding risk. Together, these studies strengthen the case for clopidogrel as a safer and more effective long-term treatment option.

Implications for Patients and Guidelines

The latest findings indicate that clopidogrel may emerge as the favored option for long-term prevention of heart attacks and strokes in people with coronary artery disease. Experts believe the drug’s generic availability, affordability, and proven effectiveness make it suitable for widespread use. However, some considerations remain.

Clopidogrel is a prescription-only drug, unlike aspirin, which can be bought over the counter. Genetic variations in how patients metabolize clopidogrel may also influence its effectiveness in some cases, although the current analysis indicates benefits are still widespread.

Certain acid-reducing medications, such as omeprazole, may interfere with clopidogrel’s action, which means doctors will need to guide patients carefully on safe combinations.

Researchers emphasize that further studies on cost-effectiveness and outcomes in more diverse populations are needed before treatment guidelines are updated worldwide. Still, the data strongly indicate that clopidogrel provides superior long-term protection without added risks.

[Source]

The post Clopidogrel Outperforms Aspirin for Long-Term Heart Protection, Study Shows appeared first on Medical Journal Daily.

The study, published in Nature Aging, found that FTL1 builds up in the hippocampus, the brain’s memory center, as mice get older. Too much of this protein disrupts brain function. Older mice with elevated FTL1 performed poorly on memory tasks. To confirm the link, scientists boosted FTL1 in younger mice.

To confirm the link, scientists boosted FTL1 in younger mice. These healthy mice quickly developed memory problems similar to older ones. But when scientists lowered FTL1 levels in aging mice, something remarkable happened: their memory improved to the level of much younger mice.

How FTL1 Affects the Brain

FTL1 helps store iron inside cells, but when it builds up in the brain, it disrupts how neurons generate and use energy. Neurons need energy to build and maintain connections, which are the pathways for learning and memory.

When FTL1 levels rise, neurons lose power. They cannot store information as effectively, leading to forgetfulness. Scientists also observed that older mice with high FTL1 had fewer connections between brain cells.

The team used advanced tools, including viruses and genetic methods, to change FTL1 levels. They then put mice through memory and learning challenges, such as solving mazes and recognizing objects. After reducing FTL1, older mice performed almost as well as young mice, proving that brain function could be restored.

The research also tested metabolism. Researchers discovered that when FTL1 levels rise, neurons struggle to produce enough energy. When they added NADH, a compound that helps with cell energy, memory problems improved. This suggests that targeting brain energy systems could be another way to help with memory loss reversal.

What This Means for Humans

While the results are exciting, the research is still at an early stage. The experiments were done only in male mice, and the human brain is far more complex. A treatment that works in mice may not work the same way in people.

Currently, there are no safe drugs that directly reduce FTL1 in humans. The methods used in the study involved genetic tools, not medicines. Researchers warn that it could take years before this discovery leads to new therapies.

Still, the findings are important because they focus on normal, age-related memory decline, not just diseases like Alzheimer’s. Almost everyone experiences some memory loss with age. By targeting FTL1, scientists may one day find a way to help a much larger group of people.

In the United States, between six and 12 million people over 65 live with mild cognitive impairment, a condition that often leads to dementia. About one-third of them develop Alzheimer’s within five years. For these individuals, new options for memory loss reversal could make a huge difference.

A New Direction in Brain Research

For decades, dementia research has centered on proteins like beta-amyloid and tau, which form clumps and tangles in the brain. The UCSF study adds a new angle by showing that iron-related proteins and energy systems may also be key to memory decline.

By focusing on FTL1, scientists are opening doors to treatments that could help almost everyone as they grow older—not just those with Alzheimer’s disease.

[Source]

The post Scientists Find Way to Reverse Memory Loss in Mice appeared first on Medical Journal Daily.

The illness is defined by an overwhelming and unrelenting fatigue that does not improve with rest, often coupled with pain, cognitive difficulties, and post-exertional malaise—a sudden worsening of symptoms after even small amounts of physical or mental activity. Despite its impact, there has been no diagnostic test, no clear biological explanation, and no proven cure.

Now, a major genetic study is beginning to change that narrative. The DecodeME project, launched in 2022 and led by scientists at the University of Edinburgh with support from patient advocacy groups, has provided the strongest evidence yet that biology—rather than behavior or psychology—plays a central role in ME/CFS.

Eight Genetic Signals—What They Reveal

Researchers examined DNA samples from more than 15,000 people with the illness and compared them to over 250,000 individuals without it. What they found was striking: eight regions of DNA where genetic differences were far more common among patients than in the general population.

These differences, often referred to as “genetic signals,” appear to cluster around two key biological systems—the immune system and the nervous system. Some of the genes identified are known to influence how the body responds to infection, a finding that echoes the experiences of many patients who report that their illness began after a viral or bacterial illness.

Others are linked to pathways involved in pain regulation, which may help explain why chronic pain is such a common feature of the condition.

Importantly, the study also showed that these genetic differences are not associated with psychiatric conditions such as depression or anxiety, helping to counter the long-standing misconception that ME/CFS is primarily psychological in nature.

Implications

The implications of these findings are significant, though researchers caution that they are only the beginning. The genetic associations discovered by DecodeME cannot yet be used to diagnose the illness, nor do they immediately translate into treatment.

What they do provide, however, is a roadmap for future research—clues that point scientists toward the biological processes most likely driving ME/CFS. By focusing on immune and neurological pathways, researchers may be able to develop targeted studies and, eventually, new therapies that address the underlying mechanisms rather than just the symptoms.

For patients, the study represents more than just scientific progress—it is also a moment of validation. ME/CFS has historically been misunderstood, with many sufferers facing disbelief from clinicians, employers, and even friends or family. The discovery that the illness is written, at least in part, into the genome underscores that it is not imagined, but rooted in biology. As Professor Chris Ponting, who leads the DecodeME study, has noted, these results mark a turning point in how the illness is perceived within the medical and research communities.

Future Directions

The DecodeME team is continuing its work, expanding the study to include participants from more diverse backgrounds and conducting deeper analyses of genetic variation. They have also made their dataset available to scientists around the world in the hope that collaboration will accelerate discoveries.

While it may take years to translate these findings into practical treatments, the momentum is now firmly on the side of progress. For a patient community that has long waited for recognition and solutions, this study offers both a clearer biological foundation and a renewed sense of hope.

[Source]

The post Major Study Reveals Genetic Roots of Chronic Fatigue Syndrome appeared first on Medical Journal Daily.

How the Gel Works

Many people with diabetes develop chronic wounds, especially on the feet, that can take months to heal—or never fully recover. One big reason is poor blood flow. In these wounds, a protein called TSP-1 acts like a “stop signal” for new blood vessels, preventing the tissue from getting the oxygen and nutrients it needs.

The new hydrogel is designed to silence that “stop signal.” It contains tiny bubble-like structures called extracellular vesicles, which naturally carry signals between cells. In this case, the vesicles have been engineered to carry a genetic message called miR-221-3p. This message tells the body to lower TSP-1 levels, allowing new blood vessels to form.

These vesicles are mixed into a gelatin-based material called GelMA hydrogel. The hydrogel acts like a soft scaffold, holding the vesicles in place at the wound site and slowly releasing them over time. This ensures that the treatment is delivered steadily, rather than all at once, which helps maintain a healing-friendly environment.

When tested on diabetic mice, the wounds treated with the gel closed significantly faster than untreated wounds. Within just 12 days, about 90 percent of the wound area had healed in the treated group, compared to much slower progress in the control group. The treated wounds also showed a greater number of tiny new blood vessels, confirming that angiogenesis had been restored.

The study’s lead author, Dr. Chuan’an Shen, noted that combining advanced tissue engineering with molecular biology allowed them to address the root cause of poor healing in diabetic wounds.

Why the Hydrogel Matters

The vesicles are mixed into a GelMA hydrogel, which feels a bit like soft jelly. This material clings to the wound, slowly releasing the healing particles over time. It also mimics the body’s own tissue structure, giving cells a good environment to grow.

In lab tests, this combination not only closed wounds faster but also increased the number of tiny new blood vessels in the healing tissue.

Diabetic wounds are a major health problem worldwide. They are difficult to treat with existing methods, and slow healing can cause serious complications.

If this hydrogel treatment works as well in humans as it did in mice, it could transform treatment for diabetic foot ulcers, which affect millions of people worldwide. Faster healing means fewer infections, a lower risk of amputations, and better quality of life.

The approach might also be adapted to help other stubborn wounds, such as those caused by poor circulation, or even to help repair other types of tissue like bone or cartilage.

Right now, the gel has only been tested in mice. The next step is to carry out clinical trials to see if it works safely and effectively in people. If successful, the diabetic wound-healing hydrogel could become a valuable tool for doctors, reducing recovery times from months to days.

[Source]

The post Smart Gel Speeds Up Healing for Diabetic Wounds appeared first on Medical Journal Daily.

The Problem with PFAS in Everyday Products

PFAS are a family of synthetic chemicals widely used in cookware, water-resistant fabrics, and food packaging due to their oil- and water-repelling properties. Teflon, or polytetrafluoroethylene (PTFE), is one of the most recognizable PFAS materials.

These substances are extremely stable because of strong carbon-fluorine bonds, which resist natural breakdown and accumulate in the environment and human tissue. Long-chain PFAS have been especially linked to serious health risks, including certain cancers and developmental issues.

Despite growing regulatory pressure to phase out PFAS, safer alternatives that match their performance have been elusive. Most non-PFAS coatings struggle to repel oil effectively, making them impractical for applications like cookware and medical devices.

Silicone-Based Solution With New Chemistry

The U of T team, led by Professor Kevin Golovin and PhD student Samuel Au, turned to polydimethylsiloxane (PDMS), a flexible silicone polymer already used in medical implants. PDMS is biocompatible, heat-resistant, and chemically inert, but until now, it could not match PFAS in oil repellency.

To enhance PDMS, the researchers developed a new technique called nanoscale fletching. This method involves attaching short PDMS chains to a base material, resembling bristles on a brush. Then, a minimal number of fluorinated groups (specifically trifluoromethyl or -CF₃ groups, the shortest possible PFAS units) are chemically bonded to the tips of these chains. These tiny groups naturally migrate to the surface, creating a nonstick layer.

“If you looked at it under a microscope, the structure would resemble the fletching on an arrow,” Au explained. This nanoscale modification allows the material to resist both water and oil, similar to conventional PFAS coatings but with significantly lower environmental risk.

Promising Test Results

The new coating scored a 6 on the repellency scale developed by the American Association of Textile Chemists and Colorists, indicating performance comparable to many conventional PFAS-based coatings. What sets it apart is its minimal use of PFAS, relying only on short-chain variants that are less toxic and unlikely to build up in the body.

While the new coating is not completely PFAS-free, it represents a major step toward safer and more sustainable materials. The researchers are optimistic about its potential for commercial use in cookware and other industries. Future efforts aim to eliminate PFAS entirely while maintaining or improving performance.

Golovin said that the ultimate goal is to develop a coating that outperforms Teflon without using any PFAS, and noted that the new material represents a significant step toward achieving that.

The team is now seeking industry collaborators to help scale the technology and reduce reliance on toxic forever chemicals in consumer products.

[Source]

The post New Nonstick Coating Works Like Teflon Without the Harmful Chemicals appeared first on Medical Journal Daily.

Found in Thousands of Low-Calorie Products

Erythritol appears in everything from protein bars to flavored water, offering about 80% the sweetness of sugar without the calories or spikes in insulin. Its widespread use has grown with the popularity of low-sugar and diabetic-friendly diets.

But this sweetener, often labeled as natural due to its presence in some fruits and fermentation processes, may carry hidden risks.

The new study examined how erythritol affects the blood-brain barrier—the brain’s critical filtering system. Researchers exposed brain blood vessel cells to amounts of erythritol comparable to what’s found in a single sugar-free beverage. They observed a damaging cascade: increased oxidative stress, reduced antioxidant activity, and even cell death.

These changes also disrupted the delicate balance between two key molecules: nitric oxide and endothelin-1. Nitric oxide relaxes blood vessels, promoting healthy blood flow, while endothelin-1 causes them to constrict. Erythritol lowered levels of nitric oxide while boosting endothelin-1, causing blood vessels to stay narrowed. This narrowing can limit the brain’s access to oxygen and nutrients, increasing the risk of ischaemic stroke.

It also weakened the cells’ natural capacity to break down blood clots. Normally, they release a compound called tissue plasminogen activator (t-PA) to break down clots. But erythritol suppressed this mechanism, potentially leaving clots to accumulate and increase the risk of stroke.

Echoes of Earlier Human Studies

The laboratory results align with previous human studies. One 2023 investigation that tracked over 4,000 individuals across the US and Europe found that those with elevated erythritol levels in their blood had nearly double the risk of experiencing a heart attack or stroke within three years.

Another study showed that 30 grams of erythritol—a typical serving in sugar-free ice cream—can make blood platelets more likely to clump, setting the stage for clot formation.

Erythritol is often promoted as a “natural” alternative to artificial sweeteners like aspartame or sucralose, and its chemistry makes it easier to substitute for sugar in recipes. Because it’s technically a sugar alcohol and produced in small amounts by the body, it has largely avoided the negative attention directed at other synthetic sweeteners.

However, experts warn that its natural origin does not guarantee safety. The U.S. Food and Drug Administration and European Food Safety Authority have approved it for consumption, but the new data suggest long-term effects may not be fully understood.

What This Means for Consumers

Researchers emphasize that their experiments were conducted on isolated cells in laboratory conditions. Human bodies are more complex, and more research—especially studies involving whole-body responses or advanced vascular models—is needed to draw final conclusions.

Still, scientists advise consumers to read labels and be mindful of erythritol intake, especially if they consume multiple servings of sugar-free products daily. Given the links to vascular dysfunction and stroke risk, moderation may be a wise approach.

[Source]

The post A Common Sugar Substitute May Damage Brain’s Protective Barrier, Raise Stroke Risk, New Research Warns appeared first on Medical Journal Daily.

Eating Late Affects Glucose Levels

A study led by Dr. Diana Díaz Rizzolo at Columbia University’s Irving Medical Center, in collaboration with the Universitat Oberta de Catalunya, explored how eating patterns affect glucose regulation. The study followed 26 adults between the ages of 50 and 70 who were either overweight or had prediabetes or type 2 diabetes. Participants were divided into two groups. One group consumed most of their calories before 5 p.m., while the other consumed 45 percent or more of their calories after that time.

Despite eating identical meals and consuming the same number of calories, the group that ate later in the day had significantly worse glucose tolerance. Dr. Díaz Rizzolo explains that this may be due to the body’s reduced ability to manage blood sugar at night. As evening approaches, insulin production slows down, and cells become less responsive to the hormone, making it more difficult for the body to control glucose levels.

Maintaining elevated glucose levels over time is linked to an increased risk of type 2 diabetes, cardiovascular disease, and chronic inflammation. The study supports the idea that eating earlier in the day may help reduce these risks, regardless of weight or diet quality.

Mood Disorders and Nighttime Meals

Meal timing may also play a role in emotional well-being. A research team from Harvard Medical School and Brigham and Women’s Hospital designed an experiment simulating shift work to examine how eating schedules affect mood.

Volunteers were split into two groups. One group followed a schedule that included meals both during daylight and nighttime hours. The other group ate only during the day, even as their internal clocks were disrupted.

After several days of circadian misalignment, the group that ate throughout both day and night showed noticeable changes in mood, including more symptoms resembling depression and anxiety. In contrast, those who stuck to daytime eating experienced no meaningful changes in their emotional state.

Dr. Frank Scheer, one of the study authors, suggests that aligning meals with the body’s natural rhythms could be a useful strategy for protecting mental health, especially in people whose schedules involve irregular sleep and wake cycles.

The Body Processes Food Better in the Morning

Additional research supports the idea that our bodies are more efficient at digesting food earlier in the day. Circadian rhythms make the digestive system more active in the morning. Insulin sensitivity is higher, which helps the body process glucose more effectively. In contrast, melatonin—a hormone that signals the body to prepare for sleep—can interfere with insulin release when food is consumed late at night or close to bedtime.

Human studies have shown that eating close to bedtime or during the biological night is associated with higher body fat and impaired glucose regulation. In weight-loss trials, participants who consumed more calories earlier in the day lost more weight and had improved metabolic markers compared to those who ate more in the evening.

Animal studies have also illustrated the effect of mistimed eating. Mice fed high-fat diets during their inactive period gained more weight and developed metabolic disorders more quickly than those fed during their active phase, even when total calorie intake was the same.

Practical Recommendations

The growing field of chrono-nutrition offers a few clear takeaways for people looking to improve their health through better meal timing:

1. Prioritize calories earlier in the day. Aim to eat larger meals at breakfast and lunch rather than saving them for dinner.
2. Keep a consistent eating window. Limiting daily eating to a span of fewer than 12 hours may support circadian health.
3. Avoid eating close to bedtime. Try to finish your last meal two to three hours before going to sleep to support digestion and metabolic function.

Researchers caution that while early evidence is promising, more long-term human studies are needed. Responses to meal timing may vary based on age, gender, and health status. However, the current science strongly suggests that meal timing is a key piece of the nutrition puzzle.

The post The Science of When to Eat for Better Metabolism, Mood, and Lifespan appeared first on Medical Journal Daily.

Infants typically weigh between two and five kilograms during their first months. In malaria-prone regions, this has long made treatment difficult. Health workers often split or dilute larger pills, increasing the chances of either underdosing or toxic effects. With this approval, that workaround may no longer be necessary.

The new formulation uses the same antimalarial agents already used for older age groups, but in smaller, carefully balanced doses. It dissolves in breast milk and has a cherry flavor, making it easier for caregivers to give and infants to swallow.

Why This Matters

In 2023, malaria claimed close to 600,000 lives, according to data from the World Health Organization. Nearly all of these deaths (around 95%) happened in Africa, with children under the age of five making up the majority of the fatalities. While malaria in newborns is less frequent than in toddlers, the lack of infant-specific medicine has left a gap in care.

Dr. Quique Bassat, director of the Barcelona Institute for Global Health, said newborn cases might be fewer, but they still require the same level of attention. “Even if numbers are lower, the need for safe and precise treatment remains,” he noted.

Babies are especially vulnerable because they cannot receive malaria vaccines until about five months of age. For infants born in malaria-endemic areas, that early window carries risk. WHO estimates suggest around 36 million pregnancies occurred in 33 African countries affected by malaria last year.

In about one-third of those cases, mothers contracted malaria during pregnancy, which raises the chance of passing the infection to their babies.

“Each baby born in these areas starts life already at risk,” said Dr. Lutz Hegemann, who oversees Novartis’ global health division.

What Comes Next

Swissmedic’s approval involved input from eight African countries, including Kenya, Nigeria, and Uganda. These countries participated in evaluating the drug through a regulatory partnership, allowing them to act quickly on final approval. Within the next 90 days, these nations are expected to authorize the treatment and begin distribution.

Novartis has stated that it intends to distribute the new infant malaria treatment on a mostly non-commercial basis. Still, health experts are urging the company to clarify what that means in practical terms.

She also warned that funding cuts and rising drug resistance continue to challenge malaria programs. Even as new tools like vaccines and mosquito control efforts expand, access remains uneven—particularly in places affected by conflict or climate-related disruptions.

A Better Fit for a Difficult Problem

The Swiss approval used a special fast-track process, reserved for treatments urgently needed in developing countries. It’s only the third time Swissmedic has used this method, which it operates in coordination with the WHO.

The move may also signal a shift in how regulators collaborate with low-resource countries. By involving local experts early in the evaluation, the system speeds up adoption without lowering safety standards.

In past years, treating newborns with malaria has been like trying to wrap a small parcel using sheets designed for furniture—too big, too imprecise, and requiring constant adjustment. With Coartem Baby, the fit becomes much more exact.

The medicine is based on familiar compounds but tuned for smaller bodies. By bringing the dose closer to the actual need, it reduces error and avoids the guesswork that once made newborn malaria treatment both risky and difficult.

[Source: 1,2]

The post Switzerland Approves First Malaria Drug for Newborns appeared first on Medical Journal Daily.

Dental Pulp Cells Can Repair Tissues Beyond the Mouth

Scientists around the world are culturing and testing dental pulp cells in the lab. At CSIRO’s Stem Cell Centre in Australia, for instance, researchers examine cultured stem‑cell samples under high‑resolution microscopes.

In the lab, DPSCs self‑renew and proliferate rapidly. Studies show that when given the right signals, DPSCs will lay down collagen and calcium to form bone or cartilage matrix and even beat and contract like muscle.

Compared with bone‑marrow stem cells, DPSCs often build mineralized (bone) tissue more quickly. In engineered joint grafts they can produce cartilage tissue in vitro. In one animal study, combining human dental pulp cells with a scaffold led to significantly more new bone growth than a scaffold alone.

Such findings give hope that wisdom‑tooth cells could one day aid in healing fractures, repairing jawbones after tumor surgery, or rebuilding degenerated cartilage in arthritic joints. Each year millions of wisdom teeth are removed and usually discarded. In the United States alone an estimated ten million molars are extracted annually.

Tooth Banking and the Future of Personalized Medicine

A growing number of biotech startups and dental clinics now offer “tooth banking” – preserving a patient’s pulp cells for possible future use. The process of collecting dental pulp stem cells begins immediately after the tooth is removed.

The extracted wisdom tooth is placed in a sterile container and transported under cold conditions to a laboratory. There, specialists extract the pulp tissue and typically freeze the stem cells within a day to preserve their viability.

Proponents note that banking one’s own DPSCs eliminates concerns about immune rejection later, and the upfront cost (comparable to cord‑blood banking) could pay off if personalized therapies are needed decades down the line.

Clinics partner with oral surgeons to harvest molars that would otherwise be discarded, turning “trash” into a long‑term biological asset. Early experiments hint at a wide range of potential therapies.

For example, cardiologists have tested injections of dental‑pulp cell secretions in rodents with heart failure, and observed improved cardiac function – suggesting that a patient’s own wisdom‑tooth cells might one day help mend a damaged heart.

In neurological studies, DPSC transplants into Alzheimer’s‑model mice produced measurable improvements in memory and brain pathology.

It can generate dopamine‑producing neurons in culture, and rodent models of Parkinson’s disease showed motor improvements with dental stem cell therapy.

DPSCs appear to secrete a cocktail of growth factors that protect nerves, reduce inflammation and even help clear toxic proteins in the brain. Outside the nervous system, laboratories report that dental pulp cells readily become osteoblast‑like and build bone in 3D scaffolds, making them promising for filling bone defects.

More Work Is Needed to Prove Safety and Efficacy

As the evidence grows, investigators are planning clinical trials of dental pulp therapies. Early stem‑cell implants (using embryonic stem cells) in Parkinson’s patients have already demonstrated that new dopamine neurons can survive and function in humans. Using DPSCs instead could avoid ethical controversies and reduce immune risk.

However, experts caution that more work is needed. Transplanted cells must be shown safe (without forming tumors) and effective in people. Scientists at universities and institutes worldwide – for example at the University of the Basque Country in Spain – continue refining protocols to turn tooth pulp into therapy. “These are easily accessible human stem cells for nerve tissue engineering,” researchers note.

They argue that routinely preserving wisdom teeth now could create a personalized “biobank” of one’s own stem cells, offering future regenerative treatments without the wait for a perfect donor match. Wisdom teeth may have been viewed as nuisances, but modern research is recasting them as biological treasure.

Before tossing those extracted molars, patients might consider the hidden value inside. In the coming years, therapies for bone injuries, neurological diseases or heart disease may indeed spring from the “medical gold” locked in wisdom tooth pulp.

[Source: 1,2]

The post “Medical Gold” From Extracted Wisdom Teeth Are Being Used to Treat a Range of Diseases appeared first on Medical Journal Daily.

Microparticles designed to release vaccines at set times

The research team’s approach involves packaging multiple doses of a vaccine into a single injection, using specially engineered microparticles that release each dose at a pre-programmed time. Instead of returning weeks or months later for a booster, a child could receive the entire course during one clinic visit.

The microparticles used in this vaccine system are built from a material group known as polyanhydrides. These particles are engineered as small, enclosed units that break down slowly once inside the body. As they degrade, they release the vaccine at specific intervals. The timing of this release depends on how the material is structured at the molecular level.

Mouse studies show immune response from delayed release

The team, led by researchers Ana Jaklenec and Robert Langer, recently demonstrated this timed delivery system in mice. The experiment involved two doses of a diphtheria vaccine: one released immediately and the second programmed to release two weeks later. The immune response in the mice mirrored what is typically seen when two separate injections are given weeks apart.

A major technical challenge was ensuring that the vaccine remains stable inside the microparticles during the delay between injection and release.

Traditional polymers like PLGA, which have been used for similar delivery systems, tend to create an acidic environment as they break down. This can damage sensitive biological materials like vaccines. The team chose polyanhydrides because they break down more slowly and produce less acidity, making them more suitable for carrying live or fragile antigens.

To identify the most effective versions of these materials, the team created a library of 23 polyanhydride types, each with slight variations in chemical makeup. They used a method called SEAL — stamped assembly of polymer layers — to form the particles and test their durability, sealing strength, and release performance.

After narrowing the list to the six most promising candidates, they tested them in mice.

Machine learning guides material design for timed release

To improve their material selection process, the researchers also developed a machine learning model. This algorithm predicted how changes in polymer composition would affect release timing, allowing them to screen hundreds of potential combinations virtually before testing a few in the lab.

Although still in early stages, this technology offers a possible shift in how vaccines are administered. If scaled successfully, it could benefit populations where returning for a second or third dose is a logistical challenge.

Clinics in rural areas, mobile vaccination units, and emergency response teams could all use a system that delivers complete protection in a single shot.

Potential for use in childhood vaccines and other treatments

Beyond childhood vaccines, the same method might be used to deliver other medications that require controlled timing, including hormone therapies or certain cancer treatments. For now, the immediate focus is on extending the interval between dose releases and testing the approach with other diseases like polio and measles.

This new form of vaccine delivery may not eliminate all barriers to global immunization, but it offers a practical way to reach more people with fewer resources.

By reducing the need for multiple appointments, it could help healthcare workers deliver lifesaving treatments more efficiently, especially in places where time and access are in short supply.

[Source]

The post How One Injection Could Deliver Multiple Vaccine Doses Ending the Need for Booster Shots appeared first on Medical Journal Daily.